Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Onesource Specialty, a newly demerged pharma CDMO, is set to benefit from the $150 billion GLP-1 weight-loss drug boom with ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

Ozempic is on everyone's lips—sometimes even literally. This revolutionary diabetes drug has, unfortunately, become a social ...

Tirzepatide, the newest weight loss drug in India, is transforming the wellness market with its hormone-mimicking effects.

The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

Last month, the scientists behind Ozempic – hailed as a ‘miracle drug’ for weight-loss – were honoured by the Breakthrough ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Sunshine may hold healing rays for a variety of autoimmune diseases such as multiple sclerosis. Scientists are turning this ...